These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 19459784)

  • 1. Anaplastic lymphoma kinase: signalling in development and disease.
    Palmer RH; Vernersson E; Grabbe C; Hallberg B
    Biochem J; 2009 May; 420(3):345-61. PubMed ID: 19459784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
    Cheng M; Ott GR
    Anticancer Agents Med Chem; 2010 Mar; 10(3):236-49. PubMed ID: 20406193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target.
    Werner MT; Zhao C; Zhang Q; Wasik MA
    Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
    Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
    J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
    Kelleher FC; McDermott R
    Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease.
    Yee HT; Ponzoni M; Merson A; Goldstein M; Scarpa A; Chilosi M; Menestrina F; Pittaluga S; de Wolf-Peeters C; Shiota M; Mori S; Frizzera G; Inghirami G
    Blood; 1996 Feb; 87(3):1081-8. PubMed ID: 8562933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NPM-ALK and the JunB transcription factor regulate the expression of cytotoxic molecules in ALK-positive, anaplastic large cell lymphoma.
    Pearson JD; Lee JK; Bacani JT; Lai R; Ingham RJ
    Int J Clin Exp Pathol; 2011 Jan; 4(2):124-33. PubMed ID: 21326808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
    Soda M; Choi YL; Enomoto M; Takada S; Yamashita Y; Ishikawa S; Fujiwara S; Watanabe H; Kurashina K; Hatanaka H; Bando M; Ohno S; Ishikawa Y; Aburatani H; Niki T; Sohara Y; Sugiyama Y; Mano H
    Nature; 2007 Aug; 448(7153):561-6. PubMed ID: 17625570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.
    Ceccon M; Merlo MEB; Mologni L; Poggio T; Varesio LM; Menotti M; Bombelli S; Rigolio R; Manazza AD; Di Giacomo F; Ambrogio C; Giudici G; Casati C; Mastini C; Compagno M; Turner SD; Gambacorti-Passerini C; Chiarle R; Voena C
    Oncogene; 2016 Jul; 35(29):3854-3865. PubMed ID: 26657151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma.
    Molavi O; Samadi N; Wu C; Lavasanifar A; Lai R
    Leuk Lymphoma; 2016 May; 57(5):1154-62. PubMed ID: 26133723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis.
    Bischof D; Pulford K; Mason DY; Morris SW
    Mol Cell Biol; 1997 Apr; 17(4):2312-25. PubMed ID: 9121481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.
    Vishwamitra D; Li Y; Wilson D; Manshouri R; Curry CV; Shi B; Tang XM; Sheehan AM; Wistuba II; Shi P; Amin HM
    Am J Pathol; 2012 May; 180(5):1772-80. PubMed ID: 22414602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.
    Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM
    Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Implications of ALK (anaplastic lymphoma kinase) in oncohematology].
    Cluzeau T; Pécuchet N; Mounier N; Vignot S
    Bull Cancer; 2010 Aug; 97(8):991-6. PubMed ID: 20483705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathobiology of ALK+ anaplastic large-cell lymphoma.
    Amin HM; Lai R
    Blood; 2007 Oct; 110(7):2259-67. PubMed ID: 17519389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma.
    Wu F; Wang P; Zhang J; Young LC; Lai R; Li L
    Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of anaplastic lymphoma kinase in pediatric cancers.
    Takita J
    Cancer Sci; 2017 Oct; 108(10):1913-1920. PubMed ID: 28756644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors.
    Amin AD; Li L; Rajan SS; Gokhale V; Groysman MJ; Pongtornpipat P; Tapia EO; Wang M; Schatz JH
    Oncotarget; 2016 Apr; 7(17):23715-29. PubMed ID: 27009859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity.
    Cussac D; Greenland C; Roche S; Bai RY; Duyster J; Morris SW; Delsol G; Allouche M; Payrastre B
    Blood; 2004 Feb; 103(4):1464-71. PubMed ID: 14563642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.